The cost of epilepsy in the United States: An estimate from population- based clinical and survey data

Charles E. Begley, Melissa Famulari, John F. Annegers, David R. Lairson, Thomas F. Reynolds, Sharon Coan, Stephanie Dubinsky, Michael E. Newmark, Cynthia Leibson, E. L. So, Walter A Rocca

Research output: Contribution to journalArticle

378 Citations (Scopus)

Abstract

Purpose: To provide 1995 estimates of the lifetime and annual cost of epilepsy in the United States using data from patients with epilepsy, and adjusting for the effects of comorbidities and socioeconomic conditions. Methods: Direct treatment-related costs of epilepsy from onset through 6 years were derived from billing and medical chart data for 608 population- based incident cases at two sites in different regions of the country. Indirect productivity-related costs were derived from a survey of 1,168 adult patients visiting regional treatment centers. Direct costs separate the effects of epilepsy and comorbidity conditions. Indirect costs account for the effects of other disabilities and socioeconomic conditions on foregone earnings and household activity. The estimates were applied to 1995 population figures to derive national projections of the lifetime and annual costs of the disorder. Results: The lifetime cost of epilepsy for an estimated 181,000 people with onset in 1995 is projected at $11.1 billion, and the annual cost for the estimated 2.3 million prevalent cases is estimated at $12.5 billion. Indirect costs account for 85% of the total and, with direct costs, are concentrated in people with intractable epilepsy. Conclusions: Direct costs attributable to epilepsy are below previous estimates. Indirect costs adjusted for the socioeconomic conditions of patients are above previous estimates. Findings indicate that epilepsy is unique in the large proportion of costs that are productivity-related, justifying further investment in the development of effective interventions.

Original languageEnglish (US)
Pages (from-to)342-351
Number of pages10
JournalEpilepsia
Volume41
Issue number3
StatePublished - 2000

Fingerprint

Epilepsy
Costs and Cost Analysis
Population
Surveys and Questionnaires
Comorbidity
Health Care Costs

Keywords

  • Cost
  • Direct
  • Indirect
  • Lifetime
  • United States

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Begley, C. E., Famulari, M., Annegers, J. F., Lairson, D. R., Reynolds, T. F., Coan, S., ... Rocca, W. A. (2000). The cost of epilepsy in the United States: An estimate from population- based clinical and survey data. Epilepsia, 41(3), 342-351.

The cost of epilepsy in the United States : An estimate from population- based clinical and survey data. / Begley, Charles E.; Famulari, Melissa; Annegers, John F.; Lairson, David R.; Reynolds, Thomas F.; Coan, Sharon; Dubinsky, Stephanie; Newmark, Michael E.; Leibson, Cynthia; So, E. L.; Rocca, Walter A.

In: Epilepsia, Vol. 41, No. 3, 2000, p. 342-351.

Research output: Contribution to journalArticle

Begley, CE, Famulari, M, Annegers, JF, Lairson, DR, Reynolds, TF, Coan, S, Dubinsky, S, Newmark, ME, Leibson, C, So, EL & Rocca, WA 2000, 'The cost of epilepsy in the United States: An estimate from population- based clinical and survey data', Epilepsia, vol. 41, no. 3, pp. 342-351.
Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S et al. The cost of epilepsy in the United States: An estimate from population- based clinical and survey data. Epilepsia. 2000;41(3):342-351.
Begley, Charles E. ; Famulari, Melissa ; Annegers, John F. ; Lairson, David R. ; Reynolds, Thomas F. ; Coan, Sharon ; Dubinsky, Stephanie ; Newmark, Michael E. ; Leibson, Cynthia ; So, E. L. ; Rocca, Walter A. / The cost of epilepsy in the United States : An estimate from population- based clinical and survey data. In: Epilepsia. 2000 ; Vol. 41, No. 3. pp. 342-351.
@article{9abe64c4abd84f2a9db303733801db86,
title = "The cost of epilepsy in the United States: An estimate from population- based clinical and survey data",
abstract = "Purpose: To provide 1995 estimates of the lifetime and annual cost of epilepsy in the United States using data from patients with epilepsy, and adjusting for the effects of comorbidities and socioeconomic conditions. Methods: Direct treatment-related costs of epilepsy from onset through 6 years were derived from billing and medical chart data for 608 population- based incident cases at two sites in different regions of the country. Indirect productivity-related costs were derived from a survey of 1,168 adult patients visiting regional treatment centers. Direct costs separate the effects of epilepsy and comorbidity conditions. Indirect costs account for the effects of other disabilities and socioeconomic conditions on foregone earnings and household activity. The estimates were applied to 1995 population figures to derive national projections of the lifetime and annual costs of the disorder. Results: The lifetime cost of epilepsy for an estimated 181,000 people with onset in 1995 is projected at $11.1 billion, and the annual cost for the estimated 2.3 million prevalent cases is estimated at $12.5 billion. Indirect costs account for 85{\%} of the total and, with direct costs, are concentrated in people with intractable epilepsy. Conclusions: Direct costs attributable to epilepsy are below previous estimates. Indirect costs adjusted for the socioeconomic conditions of patients are above previous estimates. Findings indicate that epilepsy is unique in the large proportion of costs that are productivity-related, justifying further investment in the development of effective interventions.",
keywords = "Cost, Direct, Indirect, Lifetime, United States",
author = "Begley, {Charles E.} and Melissa Famulari and Annegers, {John F.} and Lairson, {David R.} and Reynolds, {Thomas F.} and Sharon Coan and Stephanie Dubinsky and Newmark, {Michael E.} and Cynthia Leibson and So, {E. L.} and Rocca, {Walter A}",
year = "2000",
language = "English (US)",
volume = "41",
pages = "342--351",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The cost of epilepsy in the United States

T2 - An estimate from population- based clinical and survey data

AU - Begley, Charles E.

AU - Famulari, Melissa

AU - Annegers, John F.

AU - Lairson, David R.

AU - Reynolds, Thomas F.

AU - Coan, Sharon

AU - Dubinsky, Stephanie

AU - Newmark, Michael E.

AU - Leibson, Cynthia

AU - So, E. L.

AU - Rocca, Walter A

PY - 2000

Y1 - 2000

N2 - Purpose: To provide 1995 estimates of the lifetime and annual cost of epilepsy in the United States using data from patients with epilepsy, and adjusting for the effects of comorbidities and socioeconomic conditions. Methods: Direct treatment-related costs of epilepsy from onset through 6 years were derived from billing and medical chart data for 608 population- based incident cases at two sites in different regions of the country. Indirect productivity-related costs were derived from a survey of 1,168 adult patients visiting regional treatment centers. Direct costs separate the effects of epilepsy and comorbidity conditions. Indirect costs account for the effects of other disabilities and socioeconomic conditions on foregone earnings and household activity. The estimates were applied to 1995 population figures to derive national projections of the lifetime and annual costs of the disorder. Results: The lifetime cost of epilepsy for an estimated 181,000 people with onset in 1995 is projected at $11.1 billion, and the annual cost for the estimated 2.3 million prevalent cases is estimated at $12.5 billion. Indirect costs account for 85% of the total and, with direct costs, are concentrated in people with intractable epilepsy. Conclusions: Direct costs attributable to epilepsy are below previous estimates. Indirect costs adjusted for the socioeconomic conditions of patients are above previous estimates. Findings indicate that epilepsy is unique in the large proportion of costs that are productivity-related, justifying further investment in the development of effective interventions.

AB - Purpose: To provide 1995 estimates of the lifetime and annual cost of epilepsy in the United States using data from patients with epilepsy, and adjusting for the effects of comorbidities and socioeconomic conditions. Methods: Direct treatment-related costs of epilepsy from onset through 6 years were derived from billing and medical chart data for 608 population- based incident cases at two sites in different regions of the country. Indirect productivity-related costs were derived from a survey of 1,168 adult patients visiting regional treatment centers. Direct costs separate the effects of epilepsy and comorbidity conditions. Indirect costs account for the effects of other disabilities and socioeconomic conditions on foregone earnings and household activity. The estimates were applied to 1995 population figures to derive national projections of the lifetime and annual costs of the disorder. Results: The lifetime cost of epilepsy for an estimated 181,000 people with onset in 1995 is projected at $11.1 billion, and the annual cost for the estimated 2.3 million prevalent cases is estimated at $12.5 billion. Indirect costs account for 85% of the total and, with direct costs, are concentrated in people with intractable epilepsy. Conclusions: Direct costs attributable to epilepsy are below previous estimates. Indirect costs adjusted for the socioeconomic conditions of patients are above previous estimates. Findings indicate that epilepsy is unique in the large proportion of costs that are productivity-related, justifying further investment in the development of effective interventions.

KW - Cost

KW - Direct

KW - Indirect

KW - Lifetime

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=0034049224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034049224&partnerID=8YFLogxK

M3 - Article

C2 - 10714408

AN - SCOPUS:0034049224

VL - 41

SP - 342

EP - 351

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -